175 related articles for article (PubMed ID: 36499626)
41. MiR-30a-5p/CHD1 axis enhances cisplatin sensitivity of ovarian cancer cells via inactivating the Wnt/β-catenin pathway.
Wang X; Zhao H; Wang P; Zhang J; Li N; Liu Y; Zhang F; Yu Y
Anticancer Drugs; 2022 Nov; 33(10):989-998. PubMed ID: 36206129
[TBL] [Abstract][Full Text] [Related]
42. STAT3 regulated
Jin P; Liu Y; Wang R
Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 30061175
[TBL] [Abstract][Full Text] [Related]
43. Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
Dos Santos Guimarães I; Ladislau-Magescky T; Tessarollo NG; Dos Santos DZ; Gimba ERP; Sternberg C; Silva IV; Rangel LBA
Pharmacol Rep; 2018 Jun; 70(3):409-417. PubMed ID: 29627688
[TBL] [Abstract][Full Text] [Related]
44. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells.
Pink RC; Samuel P; Massa D; Caley DP; Brooks SA; Carter DR
Gynecol Oncol; 2015 Apr; 137(1):143-51. PubMed ID: 25579119
[TBL] [Abstract][Full Text] [Related]
45. Cisplatin binds to pre-miR-200b and impairs its processing to mature microRNA.
Mezencev R; Wartell RM
Neoplasma; 2018; 65(2):222-227. PubMed ID: 29534583
[TBL] [Abstract][Full Text] [Related]
46. The oncogenic Golgi phosphoprotein 3 like overexpression is associated with cisplatin resistance in ovarian carcinoma and activating the NF-κB signaling pathway.
He S; Niu G; Shang J; Deng Y; Wan Z; Zhang C; You Z; Shen H
J Exp Clin Cancer Res; 2017 Oct; 36(1):137. PubMed ID: 28978336
[TBL] [Abstract][Full Text] [Related]
47. miR-378a-3p sensitizes ovarian cancer cells to cisplatin through targeting MAPK1/GRB2.
Xu ZH; Yao TZ; Liu W
Biomed Pharmacother; 2018 Nov; 107():1410-1417. PubMed ID: 30257357
[TBL] [Abstract][Full Text] [Related]
48. p62/SQSTM1 as an oncotarget mediates cisplatin resistance through activating RIP1-NF-κB pathway in human ovarian cancer cells.
Yan XY; Zhang Y; Zhang JJ; Zhang LC; Liu YN; Wu Y; Xue YN; Lu SY; Su J; Sun LK
Cancer Sci; 2017 Jul; 108(7):1405-1413. PubMed ID: 28498503
[TBL] [Abstract][Full Text] [Related]
49. Enhancing wound healing and overcoming cisplatin resistance in ovarian cancer.
Zhang Q; Guo F; Liu H; Hong L
Int Wound J; 2024 Apr; 21(4):e14569. PubMed ID: 38158767
[TBL] [Abstract][Full Text] [Related]
50. SOD1-high fibroblasts derived exosomal miR-3960 promotes cisplatin resistance in triple-negative breast cancer by suppressing BRSK2-mediated phosphorylation of PIMREG.
Li K; Lin H; Liu A; Qiu C; Rao Z; Wang Z; Chen S; She X; Zhu S; Li P; Liu L; Wu Q; Wang G; Xu F; Li S
Cancer Lett; 2024 May; 590():216842. PubMed ID: 38582395
[TBL] [Abstract][Full Text] [Related]
51. MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1.
Vescarelli E; Gerini G; Megiorni F; Anastasiadou E; Pontecorvi P; Solito L; De Vitis C; Camero S; Marchetti C; Mancini R; Benedetti Panici P; Dominici C; Romano F; Angeloni A; Marchese C; Ceccarelli S
J Exp Clin Cancer Res; 2020 Jan; 39(1):3. PubMed ID: 31898520
[TBL] [Abstract][Full Text] [Related]
52. Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma.
Zhao H; Bi T; Qu Z; Jiang J; Cui S; Wang Y
Oncol Rep; 2014 Sep; 32(3):1003-12. PubMed ID: 25017423
[TBL] [Abstract][Full Text] [Related]
53. A novel miR-200c/c-myc negative regulatory feedback loop is essential to the EMT process, CSC biology and drug sensitivity in nasopharyngeal cancer.
Yang J; Wu SP; Wang WJ; Jin ZR; Miao XB; Wu Y; Gou DM; Liu QZ; Yao KT
Exp Cell Res; 2020 Jun; 391(2):111817. PubMed ID: 32179097
[TBL] [Abstract][Full Text] [Related]
54. Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer.
Liu MX; Siu MK; Liu SS; Yam JW; Ngan HY; Chan DW
Oncotarget; 2014 Feb; 5(4):944-58. PubMed ID: 24659709
[TBL] [Abstract][Full Text] [Related]
55. A negative feedback loop between miR-200b and the nuclear factor-κB pathway via IKBKB/IKK-β in breast cancer cells.
Wu H; Wang G; Wang Z; An S; Ye P; Luo S
FEBS J; 2016 Jun; 283(12):2259-71. PubMed ID: 26433127
[TBL] [Abstract][Full Text] [Related]
56. A Feedback Loop Between miR-30a/c-5p and DNMT1 Mediates Cisplatin Resistance in Ovarian Cancer Cells.
Han X; Zhen S; Ye Z; Lu J; Wang L; Li P; Li J; Zheng X; Li H; Chen W; Li X; Zhao L
Cell Physiol Biochem; 2017; 41(3):973-986. PubMed ID: 28222434
[TBL] [Abstract][Full Text] [Related]
57. [Expression of miR-130a in cisplatin resistant cell lines of ovarian cancer].
Yang LY; Wang HJ; Jia XB; Wang X; Luo J; Zhang XY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Jan; 43(1):60-4. PubMed ID: 22455133
[TBL] [Abstract][Full Text] [Related]
58. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A.
Wang J; Liu L
J Ovarian Res; 2021 Nov; 14(1):165. PubMed ID: 34798882
[TBL] [Abstract][Full Text] [Related]
59. Deregulation of miR-128 in ovarian cancer promotes cisplatin resistance.
Li B; Chen H; Wu N; Zhang WJ; Shang LX
Int J Gynecol Cancer; 2014 Oct; 24(8):1381-8. PubMed ID: 25248111
[TBL] [Abstract][Full Text] [Related]
60. miR-101 regulates expression of EZH2 and contributes to progression of and cisplatin resistance in epithelial ovarian cancer.
Liu L; Guo J; Yu L; Cai J; Gui T; Tang H; Song L; Wang J; Han F; Yang C; Chen C; Marks A; Wang Z
Tumour Biol; 2014 Dec; 35(12):12619-26. PubMed ID: 25260883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]